Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine



Rating:

Share or cite this content

Citations should be made in the following way:
A. J. Mahiny, R. Handgretinger, D. Hartl, M. S. D. Kormann (Tuebingen, Germany). Chemically modified mRNA as a novel treatment for cystic fibrosis. Eur Respir J 2013; 42: Suppl. 57, 747

Member's Comments

No comment yet.

Related content which might interest you: Assessment of public awareness on chronic obstructive pulmonary disease in Slovenia Source: International Congress 2014 – Management of COPD in primary care Year: 2014 Development of a national patient charter for idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 Health care system resource utilisation in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Interim analysis of the EXCITING-ILD registry Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Quality of life measures in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Health status & impact of living with idiopathic pulmonary fibrosis (IPF): UK & Ireland Delphi survey Source: International Congress 2016 – IPF clinical Year: 2016 Clinical, functional and microbiological characteristics of an adult brazilian cystic fibrosis population Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment Year: 2014 Cystic fibrosis diagnosis in adulthood as a result of study of relatives within the newborn screening programme Source: International Congress 2015 – Cystic fibrosis: assessment and treatment Year: 2015 IPF Care, a support program for patients with idiopathic pulmonary fibrosis in the UK Source: International Congress 2015 – Latest insights into chronic care Year: 2015 Characterisation of a novel symptom of chronic obstructive pulmonary disease: Bendopnoea Source: International Congress 2016 – Management of dyspnoea and exacerbations in chronic lung diseases Year: 2016 Chronic lung disease in two patients with new integrin alfa3 gene mutations Source: International Congress 2016 – Orphan diseases II Year: 2016 Prevalence of occupational and environmental exposures in Australian patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Occupational asthma, abestosis and silicosis Year: 2014 The burden of idiopathic pulmonary fibrosis reported by patients and carers in Ireland Source: International Congress 2015 – IPF: clinical aspects Year: 2015 The burden of chronic obstructive pulmonary disease (COPD) in Taiwan Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013 Inspiration: An assistance program for idiopathic pulmonary fibrosis patients on pirfenidone Source: International Congress 2014 – Respiratory symptoms in primary care populations Year: 2014 Cognition in COPD patients Source: International Congress 2016 – Best abstracts on innovative outcomes and novel interventions in respiratory physiotherapy Year: 2016 Impact of pulmonary rehabilitation on quality of life in patients with silica exposure associated with progressive massive fibrosis Source: International Congress 2014 – Occupational respiratory diseases: from drug-induced disease to COPD induced by the uranium industry Year: 2014 Repeat pulmonary rehabilitation programmes: Are they beneficial in COPD? Source: International Congress 2014 – Best posters in pulmonary rehabilitation 1 Year: 2014 Do GOLD stages of COPD severity really correspond to differences in health status? Source: Eur Respir J 2003; 22: 444-449 Year: 2003 Predicting mortality in idiopathic pulmonary fibrosis. Which parameters should be used to determine eligibility for treatment? Analysis of a UK prospective cohort Source: International Congress 2016 – The best is yet to come in terms of lung function Year: 2016